63 related articles for article (PubMed ID: 29783391)
1. Genetic variation and antipsychotic drug effects on serum lipids.
Hallman DM
Per Med; 2008 Jan; 5(1):77-81. PubMed ID: 29783391
[TBL] [Abstract][Full Text] [Related]
2. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.
Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B
Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal analysis of haplotypes and polymorphisms of the APOA5 and APOC3 genes associated with variation in serum triglyceride levels: the Bogalusa Heart Study.
Hallman DM; Srinivasan SR; Chen W; Boerwinkle E; Berenson GS
Metabolism; 2006 Dec; 55(12):1574-81. PubMed ID: 17142127
[TBL] [Abstract][Full Text] [Related]
4. Impact of apolipoprotein A5 (APOA5) polymorphisms on serum triglyceride levels in schizophrenic patients under long-term atypical antipsychotic treatment.
Hong CJ; Chen TT; Bai YM; Liou YJ; Tsai SJ
World J Biol Psychiatry; 2012 Jan; 13(1):22-9. PubMed ID: 21375366
[TBL] [Abstract][Full Text] [Related]
5. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy.
Arnedo M; Taffé P; Sahli R; Furrer H; Hirschel B; Elzi L; Weber R; Vernazza P; Bernasconi E; Darioli R; Bergmann S; Beckmann JS; Telenti A; Tarr PE;
Pharmacogenet Genomics; 2007 Sep; 17(9):755-64. PubMed ID: 17700364
[TBL] [Abstract][Full Text] [Related]
6. Prediction of genetic risk for dyslipidemia.
Yamada Y; Matsuo H; Warita S; Watanabe S; Kato K; Oguri M; Yokoi K; Metoki N; Yoshida H; Satoh K; Ichihara S; Aoyagi Y; Yasunaga A; Park H; Tanaka M; Nozawa Y
Genomics; 2007 Nov; 90(5):551-8. PubMed ID: 17919884
[TBL] [Abstract][Full Text] [Related]
7. Association of APOA5 and APOC3 gene polymorphisms with plasma apolipoprotein A5 level in patients with metabolic syndrome.
Niculescu LS; Vlădică M; Sima AV
Biochem Biophys Res Commun; 2010 Jan; 391(1):587-91. PubMed ID: 19932084
[TBL] [Abstract][Full Text] [Related]
8. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein A5 and apolipoprotein C3 single nucleotide polymorphisms are correlated with an increased risk of coronary heart disease: a case-control and meta-analysis study.
Yang G; Lei MM; Yu CL; Liu XX; An Z; Song CL
Lipids Health Dis; 2015 Sep; 14():113. PubMed ID: 26387083
[TBL] [Abstract][Full Text] [Related]
10. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes.
Dallinga-Thie GM; van Tol A; Hattori H; van Vark-van der Zee LC; Jansen H; Sijbrands EJ;
Diabetologia; 2006 Jul; 49(7):1505-11. PubMed ID: 16752169
[TBL] [Abstract][Full Text] [Related]
11. Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction.
De Caterina R; Talmud PJ; Merlini PA; Foco L; Pastorino R; Altshuler D; Mauri F; Peyvandi F; Lina D; Kathiresan S; Bernardinelli L; Ardissino D;
Atherosclerosis; 2011 Feb; 214(2):397-403. PubMed ID: 21130994
[TBL] [Abstract][Full Text] [Related]
12. Effect of apolipoprotein C3 genetic polymorphisms on serum lipid levels and the risk of intracerebral hemorrhage.
Jiang Y; Ma J; Li H; Liu Y; You C
Lipids Health Dis; 2015 May; 14():48. PubMed ID: 25994187
[TBL] [Abstract][Full Text] [Related]
13. Significant association of APOA5 and APOC3 gene polymorphisms with meat quality traits in Kele pigs.
Hui YT; Yang YQ; Liu RY; Zhang YY; Xiang CJ; Liu ZZ; Ding YH; Zhang YL; Wang BR
Genet Mol Res; 2013 Sep; 12(3):3643-50. PubMed ID: 24085428
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
Arranz MJ; de Leon J
Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
[TBL] [Abstract][Full Text] [Related]
15. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
16. Association of APOA5 -1131T>C polymorphism and serum lipid levels in patients with type 2 diabetes.
Celap I; Simundic AM; Nikolac N; Kackov S; Katalinic D
DNA Cell Biol; 2013 Oct; 32(10):589-93. PubMed ID: 23919616
[TBL] [Abstract][Full Text] [Related]
17. Searching susceptibility genes for antipsychotic-induced weight gain: is the 5-HT2C receptor gene a promising candidate?
Hong KS; Park T
Per Med; 2007 Aug; 4(3):357-361. PubMed ID: 29788662
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effects of genetic variants of APOA5 and BTN2A1 on dyslipidemia or metabolic syndrome.
Hiramatsu M; Oguri M; Kato K; Horibe H; Fujimaki T; Watanabe S; Satoh K; Aoyagi Y; Tanaka M; Shin DJ; Lee JH; Jang Y; Yamada Y
Int J Mol Med; 2012 Jul; 30(1):185-92. PubMed ID: 22576629
[TBL] [Abstract][Full Text] [Related]
19. Impact of APOA5/A4/C3 genetic polymorphisms on lipid variables and cardiovascular disease risk in French men.
Dallongeville J; Cottel D; Montaye M; Codron V; Amouyel P; Helbecque N
Int J Cardiol; 2006 Jan; 106(2):152-6. PubMed ID: 16321685
[TBL] [Abstract][Full Text] [Related]
20. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study.
Dursun SM; Szemis A; Andrews H; Reveley MA
J Psychiatry Neurosci; 1999 Nov; 24(5):453-5. PubMed ID: 10586536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
